Best of ASCO 2025, Milwaukee

Milwaukee, WI US
July 26, 2025 to July 27, 2025

This CME-accredited oncology conference, Best of ASCO 2025, Milwaukee, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2025 ASCO® Annual Meeting (ASCO2025) in June 2025. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2025 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

  • Binay Shah, MD, MHA - Binaytara

Conference Chair:

  • Guru Subramanian Guru Murthy, MD, MS - Medical College of Wisconsin 

  • Thomas Giever, DO, MBA - Medical College of Wisconsin

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  • Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  • Explain how to effectively manage side-effects associated with cancer treatment
  • Review abstracts presented at ASCO® 2025 and discuss their application in clinical settings

 

Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-020-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
04/01/2025
Course expires: 
09/27/2025
Event starts: 
07/26/2025 - 8:00am PDT
Event ends: 
07/27/2025 - 3:00pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - SATURDAY, JULY 26, 2025

All times below are listed in Central Daylight Time (CDT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 08:05 AM  Welcome

08:05 AM – 09:35 AM  Session 1 - Hematologic Malignancies 

Session Chair: Meera Mohan, MD

08:05 AM – 08:35 AM  MDS/Leukemias - Lyndsey Runaas, MD

08:35 AM – 09:05 AM  Multiple Myeloma - Anita D'Souza, MD

09:05 AM – 09:35 AM  Lymphoma & CLL - Kaitlin Annunzio, DO, MS

09:35 AM – 09:45 AM  Break & Exhibits

09:45 AM – 11:05 AM  Session 2 - General Oncology 

Session Chair: Callisia N. Clarke, MD, MS, FACS, FSSO

09:45 AM – 10:05 AM  Sarcoma - John Charlson, MD

10:05 AM – 10:25 AM  Skin Cancers - Amy Harker-Murray, MD

10:25 AM – 10:45 AM  Advances in the Management of Ovarian Cancer

10:45 AM – 11:05 AM  Management of Cervical and Endometrial Cancers - Recent Updates - Christina Small-Tom, MD, MPH

11:05 AM – 11:55 AM  Session 3 - Tumor-Board Style Discussion: Challenging Cases

Session Chairs: Guru Subramanian Guru Murthy, MD, MS & Thomas Giever, DO, MBA

Case-Based Discussion

11:55 AM – 12:15 PM  Access to Cancer Care in LMIC - Binay Shah, MD, MHA 

12:15 PM – 01:15 PM  Lunch & Exhibits

01:15 PM – 02:45 PM  Session 4 - Genitourinary Cancer

Session Chair

01:15 PM – 01:45 PM  Prostate Cancer - Kathryn Bylow, MD

01:45 PM – 02:15 PM  Bladder Cancer 

02:15 PM – 02:45 PM  Kidney Cancer - Hamid Emamekhoo, MD

02:45 PM – 03:15 PM  Break and Exhibits 

Product Theater Sponsored by Pfizer

Title: Review of Evidence-Based Data from an Antibody-Drug Conjugate in Combination with a PD-1 Inhibitor for 1L la/mUC

*This is a non-CME accredited activity*

03:15 PM – 04:45 PM  Session 5 - Gastrointestinal Cancer

Session Chair: Carrie Peterson, MD, MS, FASCRS

03:15 PM – 03:45 PM  Upper GI Cancer - Alexandria Phan, MD, FACP

03:45 PM – 04:15 PM  Hepatobiliary and Pancreatic Malignancies - Mandana Kamgar, MD, MPH

04:15 PM – 04:45 PM  Colorectal Cancer - Ardaman Shergill, MD

04:45 PM – 05:30 PM  Reception and Networking

 

DAY 2 - SUNDAY, JULY 27, 2025

 

07:00 AM – 08:00 AM  Registration, Breakfast, and Exhibits 

08:00 AM – 09:30 AM  Session 6 - Breast Cancer

Session Chair: Adrienne Cobb, MD, MS

08:00 AM – 08:30 AM  Hormone Receptor Positive Breast Cancer - Kari Wisinski, MD

08:30 AM – 09:00 AM  Triple Negative Breast Cancer - Nusayba Bagegni, MD

09:00 AM – 09:30 AM  HER2-Positive Breast Cancer - Sailaja Kamaraju, MD

09:30 AM – 10:20 AM  Session 7 Tumor-Board Style Discussion: Challenging Cases

Session Chairs: Guru Subramanian Guru Murthy, MD, MS; Thomas Giever, DO, MBA

Case-Based Discussion 

10:20 AM – 10:30 AM  Break and Exhibits

10:30 AM – 12:00 PM  Session 8 - Thoracic Oncology

Session Chair: Janet Retseck, MD, PhD

10:30 AM – 11:00 AM  Early-Stage Non-Small Cell Lung Cancer - Kathleen Kennedy, MD

11:00 AM – 11:30 AM  Metastatic Non-Small Cell Lung Cancer - Jonathan Thompson, MD, MS

11:30 AM – 12:00 PM  Small Cell Lung Cancer - Hui-Zi Chen, MD, PhD

12:00 PM  Adjourn

Milwaukee Marriott Downtown
625 N Milwaukee St
Milwaukee, WI 53202
United States

A limited number of rooms have been booked at the Milwaukee Marriott Downtown at a discounted nightly rate for this conference's attendees and sponsors. Please book your room at this link by July 1st, 2025 to receive the discounted group rate.  

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Thomas Giever

has no relevant financial relationships to disclose at this time.

Guru Subramanian Guru Murthy, MD, MS

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Other) with Kite;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with BeiGene;.
Speaker/Topic Presenter(s)

Nusayba Bagegni, MD

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Sermonix Pharmaceuticals LLC;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Professional Services) with Curio Science;.
has a financial relationship (Professional Services) with NCCN;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Onclive;.
has a financial relationship (Professional Services) with Aptitude Health;.
has a financial relationship (Grant Or Contract) with Stemline Therapeutics ;.
has a financial relationship (Grant Or Contract) with Sarah Cannon Development Innovations;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Veracyte Inc. ;.
has a financial relationship (Professional Services) with Missouri Oncology Society;.

Huizi Chen, MD PhD

has a financial relationship (Independent contractor) with Jazz Pharmaceuticals;.

Anita D'Souza, MD, MS

has a financial relationship (Grant Or Contract) with Janssen, BMS, Pfizer, Prothena, Kedrion;.
has a financial relationship (Grant Or Contract) with Janssen, Prothena, BMS;.
has a financial relationship (Grant Or Contract) with Abbvie, Alexion, Prothena, Novartis, Regneron, Janssen, Sanofi;.

Sailaja Kamaraju

has no relevant financial relationships to disclose at this time.

Mandana Kamgar, MD, MPH

has a financial relationship (Grant Or Contract) with Cornerstone;.
has a financial relationship (Grant Or Contract) with ONECELL;.

Ardaman Shergill, MD MSPH

has a financial relationship (Professional Services) with Advisory Board: Iterion therapeutics, Revolution Medicine, Ipsen, Merus, Guardant, Pfizer, Regeneron/Sanofi and Catalyst Pharmaceuticals. Honorarium /Travel/Lodging: CCF, CCS, Cure CRC Summit, Great debates, Takeda, OncLive, OSCO, ASCO , ACPMP, ;.

Christina Small-Tom

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • AstraZeneca
  • Exact Sciences
  • Novartis

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-020-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binaytara.org/ASCOMilwaukee

 

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.